CSL Limited Sponsored ADR (OTCMKTS:CSLLY - Get Free Report)'s share price dropped 0.5% during mid-day trading on Wednesday . The stock traded as low as $79.65 and last traded at $80.15. Approximately 35,518 shares were traded during mid-day trading, a decline of 52% from the average daily volume of 73,281 shares. The stock had previously closed at $80.55.
CSL Price Performance
The firm has a 50 day moving average of $79.02 and a 200-day moving average of $81.01. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.86 and a quick ratio of 0.85.
About CSL
(
Get Free Report)
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CSL, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CSL wasn't on the list.
While CSL currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
